Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3416
IPSCIO Record ID: 5889
IPSCIO Record ID: 26568
IPSCIO Record ID: 367356
The Lead Product shall mean xx-002, a combination of GSSG and cisplatin (10001 molar ratio), including the salts, esters, metabolites, tautomers, isomers, conjugates and complexes thereof.
NOV-002 is in a pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 has also demonstrated positive results in Phase 2 trials for other cancer indications. NOV-002 is also in Phase 2 development for early-stage breast cancer and chemotherapy-resistant ovarian cancer.
NOV-205 is in Phase 1b development for chronic hepatitis C non-responders.
IPSCIO Record ID: 276397
A clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
IPSCIO Record ID: 319042
Uproleselan is a glycomimetic drug candidate and a specific E-selectin inhibitor that is being developed to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.
E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering the circulation where they can be more readily killed by chemotherapy. Glycomimetics are molecules that mimic the structure of carbohydrates involved in biological processes.
IPSCIO Record ID: 313340
Licensor is a late-stage clinical company developing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer.
IPSCIO Record ID: 217567
AE37 is an immunotherapeutic vaccine for prostate cancer. AE37, an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.
Trade name AE37
IPSCIO Record ID: 42526
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
IPSCIO Record ID: 27631